Tapering vortioxetine

Medically reviewed by: Ruben de Groot, doctor Last reviewed:

Vortioxetine, marketed as Brintellix in Europe, has a relatively long elimination half-life. Its concentration therefore declines more gradually after a dose reduction than many shorter-acting antidepressants. Nevertheless, withdrawal symptoms can still occur after vortioxetine is reduced or stopped.

What is vortioxetine?

Vortioxetine is an antidepressant that inhibits the serotonin transporter and also affects several serotonin receptors.

It is used to treat major depressive episodes in adults.

Standard tablet strengths include 5, 10, 15 and 20 mg. An oral liquid formulation is also available, making smaller doses possible.

The half-life of vortioxetine

The mean elimination half-life of vortioxetine is approximately 66 hours.

This means that the amount of active drug does not fall sharply within a single day after stopping. It takes several days for the concentration to decrease by half.

The main metabolite of vortioxetine is pharmacologically inactive. Its prolonged decline is therefore primarily due to vortioxetine itself.

This pharmacokinetic profile generally produces a slower fall in drug exposure than is seen with many short-acting antidepressants.

Can vortioxetine cause withdrawal?

Yes.

In the original clinical trials, abrupt discontinuation was not associated with a clinically relevant increase in discontinuation symptoms compared with placebo.

However, discontinuation symptoms have subsequently been reported after marketing.

Current product information lists symptoms including:

  • dizziness;
  • headache;
  • sensory disturbances;
  • electric-shock sensations;
  • sleep disturbance;
  • nausea or vomiting;
  • anxiety;
  • irritability;
  • agitation;
  • fatigue;
  • tremor.

These symptoms may occur during the first week after discontinuation.

Current product information therefore states that gradual dose reduction may be considered, while also noting that there are insufficient data to recommend one specific vortioxetine tapering schedule.

Why not automatically stop abruptly?

The long half-life means that stopping vortioxetine is pharmacokinetically less abrupt than stopping a short-acting antidepressant such as paroxetine or venlafaxine.

That does not mean that every patient can move from the lowest dose to zero without symptoms.

Relevant factors include:

  • duration of treatment;
  • previous antidepressant withdrawal;
  • previous difficulty with dose reduction;
  • current dose;
  • individual sensitivity;
  • simultaneous changes to other psychotropic medication.

If significant withdrawal has occurred previously, a more gradual approach may be appropriate.

Read more about antidepressant withdrawal.

What tapering strategies are available?

Standard tablet strengths

For someone without a history of tapering difficulties, dose reduction using the available strengths may be sufficient.

Smaller dose reductions

If larger reductions cause symptoms, smaller proportional reductions can be considered.

Vortioxetine is also available as oral drops. This can make smaller daily doses possible than standard tablets alone.

Longer stabilisation periods

The next reduction does not have to occur on a predetermined date.

If symptoms develop after a dose reduction, it may be preferable to stabilise before reducing the dose again.

Read more about hyperbolic tapering.

Is hyperbolic tapering relevant?

Potentially.

The general principle in antidepressant tapering is that dose and pharmacological effect are not linearly related. Smaller reductions may therefore be required at the lower end of the dose range.

This does not mean that every patient needs to reduce vortioxetine one milligram at a time.

The degree of precision required should primarily be determined by the individual's response to previous reductions.

Can fluoxetine bridging be used?

A technical protocol published in 2025 identifies vortioxetine as one of the serotonergic antidepressants for which fluoxetine substitution may be considered.

This does not mean that bridging is routinely required.

Vortioxetine already has a relatively long half-life and is available as an oral liquid.

Fluoxetine bridging may therefore be more relevant when a person develops recurrent, clinically significant withdrawal despite a carefully conducted vortioxetine taper, or when there is another practical reason to change strategy.

There is also an important interaction: fluoxetine inhibits CYP2D6, while CYP2D6 plays an important role in vortioxetine metabolism. Temporary co-administration may therefore increase exposure to vortioxetine.

Any such transition should be medically planned.

Read more about fluoxetine bridging.

Withdrawal or recurrence of depression?

This distinction matters.

Withdrawal often begins relatively soon after a dose reduction and may include symptoms that are not characteristic of a depressive episode, such as dizziness, electric-shock sensations or other sensory disturbances.

Recurrence of depression can also cause:

  • low mood;
  • anxiety;
  • sleep disturbance;
  • fatigue;
  • concentration problems.

The two can sometimes overlap.

We therefore consider not only which symptoms are present, but also when they started, how closely they relate to dose changes and what happened during previous medication changes.

When is medical assessment important?

Seek medical assessment when:

  • symptoms are severe;
  • functioning deteriorates substantially;
  • suicidal thoughts occur;
  • severe agitation or psychiatric destabilisation develops;
  • it is unclear whether symptoms represent withdrawal or recurrence;
  • several psychotropic medicines are being changed at the same time.

Acute suicidality or another psychiatric crisis requires appropriate urgent or emergency mental-health care rather than a planned outpatient tapering pathway.

How does the Medicatie Afbouwpoli approach vortioxetine?

We first establish:

  • why vortioxetine was originally prescribed;
  • how long it has been used;
  • current and previous doses;
  • benefits and adverse effects;
  • previous discontinuation attempts;
  • other medication;
  • current psychiatric stability;
  • personal preferences and practical options.

We then assess whether standard tapering is sufficient or whether smaller reductions or another strategy are appropriate.

Sources

  • European Medicines Agency. Brintellix — Product Information.
  • NICE. Depression in adults: treatment and management (NG222).
  • Shapiro B, Cohrs D. Fluoxetine substitution for deprescribing antidepressants: a technical approach. Journal of Psychiatry & Neuroscience. 2025;50(4)–E209.

Further reading

This page provides general medical information and is not an individual tapering prescription.